Press Release · Evogene
Evogene Schedules Third Quarter 2026 Financial Results Release
Distributed by Major Health News · Originally issued via PR Newswire
Zoom conference call scheduled for November 19, 2026, 9:00 AM ET
REHOVOT, Israel, Nov. 5, 2026 — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter 2026, on Thursday, November 19, 2026.
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
Contact:
[email protected]
Tel: +972-8-9311901
SOURCE Evogene
About Evogene:
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.